Revenue Growth Benchmarks
Top-line performance metrics of companies across industries and countries
Global Medical Devices and Technology Companies
US companies have taken the lead in CAGR over the past 5 years, followed by China and Japan. Meanwhile, European medical device companies lagged during the same period, with CAGR remaining below 5%.
[ 1: LTM Sales in USD Biliion | Red Shading: Companies with negative growth in period | Green Shading: Top 10 companies by growth rank in period ]
Company | HQ | Reported | Latest | LTM | year-on-year % | CAGR | Growth Rank | ||||||||||||
Currency | FQ | Sales1 | 3m | 6m | 9m | ltm | 1y | 2y | 3y | 5y | 6m | LTM | 3ycagr | 5ycagr | |||||
Abbott Laboratories | USA | USD | 2023-12 | 40.11 | 1.5% | -0.6% | -4.4% | -8.1% | -8.1% | -3.5% | 5.0% | 5.6% | 33 | 38 | 35 | 25 | |||
Medtronic PLC | IRL | USD | 2024-01 | 32.32 | 4.7% | 5.0% | 4.8% | 5.0% | -1.4% | 1.8% | 2.6% | 0.8% | 28 | 30 | 38 | 37 | |||
Stryker Corp | USA | USD | 2023-12 | 20.50 | 11.8% | 10.8% | 10.9% | 11.1% | 11.1% | 9.5% | 12.6% | 8.5% | 17 | 19 | 17 | 18 | |||
Boston Scientific Corp | USA | USD | 2023-12 | 14.24 | 14.9% | 13.1% | 12.4% | 12.3% | 12.3% | 9.4% | 12.8% | 7.7% | 12 | 17 | 16 | 20 | |||
Intuitive Surgical Inc | USA | USD | 2023-12 | 7.12 | 16.5% | 14.3% | 14.6% | 14.5% | 14.5% | 11.7% | 17.8% | 13.9% | 10 | 14 | 13 | 11 | |||
Olympus Corp | JPN | JPY | 2023-12 | 6.54 | 6.5% | 4.2% | 5.3% | 8.5% | 17.6% | 9.9% | 5.3% | 2.3% | 29 | 22 | 34 | 31 | |||
Terumo Corp | JPN | JPY | 2023-12 | 6.32 | 11.4% | 11.2% | 10.5% | 10.9% | 16.6% | 15.6% | 9.3% | 6.9% | 16 | 20 | 23 | 22 | |||
Edwards Lifesciences Corp | USA | USD | 2023-12 | 6.00 | 13.8% | 13.0% | 12.5% | 11.6% | 11.6% | 7.1% | 11.0% | 10.0% | 14 | 18 | 21 | 15 | |||
Smith & Nephew PLC | GBR | USD | 2023-12 | 5.55 | na | 7.6% | na | 6.4% | 6.4% | 3.2% | 6.8% | 2.5% | 22 | 28 | 29 | 30 | |||
Hoya Corp | JPN | JPY | 2023-12 | 5.54 | 13.8% | 9.4% | 7.8% | 8.1% | 9.5% | 14.7% | 8.0% | 6.3% | 20 | 23 | 27 | 23 | |||
Shenzhen Mindray Bio-Medical | CHN | CNY | 2023-09 | 4.87 | 11.2% | 15.8% | 17.2% | 17.8% | 20.2% | 20.2% | 22.4% | 22.1% | 9 | 11 | 10 | 7 | |||
ResMed Inc | USA | USD | 2023-12 | 4.50 | 12.5% | 14.2% | 16.8% | 19.7% | 18.0% | 14.9% | 12.6% | 12.5% | 11 | 8 | 18 | 14 | |||
Sonova Holding AG | CHE | CHF | 2023-09 | 3.97 | na | -5.1% | na | 1.1% | 11.1% | 19.9% | 8.6% | 7.2% | 37 | 35 | 25 | 21 | |||
Insulet Corp | USA | USD | 2023-12 | 1.70 | 37.9% | 32.7% | 32.6% | 30.0% | 30.0% | 24.3% | 23.3% | 24.7% | 3 | 4 | 8 | 6 | |||
Haemonetics Corp | USA | USD | 2023-12 | 1.27 | 10.1% | 8.6% | 11.7% | 12.5% | 17.7% | 15.9% | 5.7% | 5.3% | 21 | 16 | 31 | 26 | |||
Jeol Ltd | JPN | JPY | 2023-12 | 1.16 | -11.2% | -0.8% | -0.8% | 4.2% | 17.5% | 21.4% | 11.5% | 9.2% | 35 | 33 | 19 | 16 | |||
LivaNova PLC | GBR | USD | 2023-12 | 1.15 | 12.8% | 13.0% | 13.9% | 12.9% | 12.9% | 5.6% | 7.3% | 0.8% | 13 | 15 | 28 | 38 | |||
Omnicell Inc | USA | USD | 2023-12 | 1.15 | -13.0% | -13.7% | -12.3% | -11.5% | -11.5% | 0.7% | 8.7% | 7.8% | 38 | 39 | 24 | 19 | |||
Medmix AG | CHE | CHF | 2023-12 | 1.07 | 4.1% | 6.4% | 11.0% | 19.2% | 2.0% | 3.2% | 11.5% | 1.4% | 25 | 10 | 20 | 35 | |||
Fukuda Denshi Co Ltd | JPN | JPY | 2023-12 | 1.00 | 6.0% | 6.5% | 6.2% | 6.0% | 1.9% | -4.2% | 0.3% | 0.9% | 24 | 29 | 39 | 36 | |||
Shockwave Medical Inc | USA | USD | 2023-12 | 0.73 | 40.9% | 41.3% | 43.7% | 49.1% | 49.1% | 75.5% | 120.9% | 126.5% | 1 | 2 | 1 | 1 | |||
Ambu A/S | DNK | DKK | 2023-12 | 0.71 | 10.8% | 9.5% | 8.3% | 7.7% | 7.4% | 9.1% | 10.2% | 12.9% | 19 | 26 | 22 | 13 | |||
Shenzhen New Ind. Biomedical Engineering | USA | USD | 2023-12 | 0.62 | 39.6% | 40.0% | 46.8% | 53.2% | 53.2% | 63.6% | 75.6% | 65.3% | 2 | 1 | 2 | 2 | |||
Shenzhen New Industries Biomedical Eng | CHN | CNY | 2023-09 | 0.52 | 18.5% | 30.8% | 26.6% | 24.1% | 19.7% | 17.8% | 21.9% | 21.7% | 5 | 5 | 11 | 8 | |||
iRhythm Technologies Inc | USA | USD | 2023-12 | 0.49 | 17.7% | 18.8% | 19.7% | 19.9% | 19.9% | 23.5% | 22.9% | 27.3% | 7 | 6 | 9 | 5 | |||
Alphatec Holdings Inc | USA | USD | 2023-12 | 0.48 | 30.2% | 30.9% | 33.3% | 37.4% | 37.4% | 40.8% | 49.3% | 39.4% | 4 | 3 | 4 | 4 | |||
Accuray Inc | USA | USD | 2023-12 | 0.45 | -6.6% | -0.1% | 2.5% | 7.2% | 4.1% | 6.3% | 5.3% | 2.0% | 32 | 27 | 33 | 33 | |||
Nevro Corp | USA | USD | 2023-12 | 0.43 | 2.0% | 2.7% | 3.2% | 4.6% | 4.6% | 4.8% | 5.5% | 1.9% | 31 | 32 | 32 | 34 | |||
OraSure Technologies Inc | USA | USD | 2023-12 | 0.41 | -38.3% | -31.1% | -21.7% | 4.6% | 4.6% | 31.7% | 33.2% | 17.4% | 39 | 31 | 5 | 10 | |||
Ion Beam Applications SA | BEL | EUR | 2023-06 | 0.39 | na | 5.9% | na | 10.4% | 15.4% | 7.6% | 8.5% | 8.8% | 27 | 21 | 26 | 17 | |||
Japan Lifeline Co Ltd | JPN | JPY | 2023-12 | 0.37 | 1.2% | -0.7% | -0.5% | 1.2% | 0.5% | 0.5% | 0.0% | 4.1% | 34 | 34 | 40 | 27 | |||
Shofu Inc | JPN | JPY | 2023-12 | 0.24 | 13.2% | 9.5% | 7.0% | 8.0% | 12.6% | 13.3% | 6.7% | 5.7% | 18 | 25 | 30 | 24 | |||
Paragon 28 Inc | USA | USD | 2023-12 | 0.22 | 17.6% | 16.2% | 17.4% | 19.3% | 19.3% | 21.1% | 24.9% | na | 8 | 9 | 7 | - | |||
LeMaitre Vascular Inc | USA | USD | 2023-12 | 0.19 | 19.4% | 20.4% | 19.9% | 19.7% | 19.7% | 11.9% | 14.4% | 12.9% | 6 | 7 | 15 | 12 | |||
Zynex Inc | USA | USD | 2023-12 | 0.18 | -3.1% | 7.6% | 11.9% | 16.5% | 16.5% | 18.9% | 32.0% | 42.0% | 23 | 13 | 6 | 3 | |||
Mani Inc | JPN | JPY | 2023-11 | 0.18 | 16.5% | 11.9% | 16.0% | 17.0% | 19.9% | 19.4% | 17.2% | 4.0% | 15 | 12 | 14 | 28 | |||
RION Co Ltd | JPN | JPY | 2023-12 | 0.18 | 3.7% | 5.9% | 9.0% | 8.1% | 5.4% | 8.0% | 3.6% | 3.2% | 26 | 24 | 37 | 29 | |||
Atrion Corp | USA | USD | 2023-12 | 0.17 | 1.7% | -2.3% | -5.2% | -7.7% | -7.7% | 1.3% | 4.7% | 2.1% | 36 | 37 | 36 | 32 | |||
Cerus Corp | USA | USD | 2023-12 | 0.16 | 6.2% | 3.5% | 0.6% | -3.5% | -3.5% | 9.3% | 19.4% | 20.8% | 30 | 36 | 12 | 9 | |||
Cue Health Inc | USA | USD | 2023-12 | 0.06 | -88.1% | -84.9% | -86.6% | -86.5% | -86.5% | -67.7% | 61.0% | na | 40 | 40 | 3 | - | |||
Source: Annual Filings, Company Website | |||||||||||||||||||
Decide Fearlessly
Aranca is a global research analytics and advisory firm with over 20 years of experience in helping organizations take strategic business and investment decisions fearlessly and with utmost conviction.
Reach out to us
© , Aranca. All rights reserved.